Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Neurocrine Biosciences, Inc shares valued at $13,440,281 were sold by GORMAN KEVIN CHARLES on Aug 07 ’25. At $126.41 per share, GORMAN KEVIN CHARLES sold 106,322 shares. The insider’s holdings dropped to 514,596 shares worth approximately $67.73 million following the completion of this transaction.
Also, KEVIN CHARLES GORMAN purchased 106,322 shares, netting a total of over 13,654,934 in proceeds.
Before that, Delaet Ingrid had sold 457 shares from its account. In a trade valued at $61,695, the Chief Regulatory Officer traded Neurocrine Biosciences, Inc shares for $135.00 each. Upon closing the transaction, the insider’s holdings decreased to 457 shares, worth approximately $0.62 million.
As published in their initiating research note from Truist on July 21, 2025, Neurocrine Biosciences, Inc [NBIX] has been a Buy and the price target has been revised to $163. Analysts at Goldman started covering the stock with ‘”a Buy”‘ outlook in a report released in early July. As of April 15, 2025, Needham has increased its “Hold” rating to a “Buy” for NBIX. Earlier on April 14, 2025, RBC Capital Mkts upgraded its rating. Their new recommendation was “an Outperform” for NBIX stock which previously was a “a Sector perform”.
Analyzing NBIX Stock Performance
On last trading session, Neurocrine Biosciences, Inc [NASDAQ: NBIX] rose 2.12% to $131.62. The stock’s lowest price that day was $129.85, but it reached a high of $131.79 in the same session. During the last five days, there has been a surge of approximately 2.48%. Over the course of the year, Neurocrine Biosciences, Inc shares have dropped approximately -10.66%. Shares of the company reached a 52-week high of $154.61 on 01/30/25 and a 52-week low of $84.23 on 04/09/25.
Support And Resistance Levels for Neurocrine Biosciences, Inc (NBIX)
According to the 24-hour chart, there is a support level at 130.38, which, if violated, would cause prices to drop to 129.15. In the upper region, resistance lies at 132.32. The next price resistance is at 133.03. RSI (Relative Strength Index) is 54.88 on the 14-day chart, showing neutral technical sentiment.
Is Neurocrine Biosciences, Inc subject to short interest?
Stocks of Neurocrine Biosciences, Inc saw a sharp steep in short interest on 2025-07-31 dropping by -0.68 million shares to 2.85 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 3.53 million shares. A decline of -23.85% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.1 of the overall float, the days-to-cover ratio (short ratio) decline to 3.1.
Which companies own the most shares of Neurocrine Biosciences, Inc (NBIX)?
In terms of Neurocrine Biosciences, Inc share price expectations, FactSet research, analysts set an average price target of 163 in the next 12 months, up nearly 26.46% from the previous closing price of $128.89. Analysts anticipate Neurocrine Biosciences, Inc stock to reach 175 by 2025, with the lowest price target being 150. In spite of this, 14 analysts ranked Neurocrine Biosciences, Inc stock as Buy at the end of 2025. On February 11, 2025, Deutsche Bank assigned a price target of “a Hold” to the stock and initiated coverage with a $138.
